SureTrader
Interactive Brokers Advertisement
Home > Boards > US Listed > Medical - Drugs >

MEI Pharma, Inc. (MEIP)

MEIP RSS Feed
Add MEIP Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 10/14/2017 6:16:10 PM - Followers: 90 - Board type: Free - Posts Today: 0


MEI Pharma (Nasdaq: MEIP) is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. Our portfolio of drug candidates includes Pracinostat, an oral HDAC inhibitor being developed in combination with azacitidine for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Our clinical development pipeline also includes ME-401, a highly selective oral PI3K delta inhibitor, and ME-344, a novel mitochondrial inhibitor.

http://www.meipharma.com/our-programs/pracinostat

In August 2016, we announced that the U.S. Food & Drug Administration granted Breakthrough Therapy Designation for Pracinostat in combination with azacitidine for the treatment of patients with newly diagnosed AML who are ≥75 years of age or unfit for intensive chemotherapy. Later that month, we entered into an exclusive licensing, development and commercialization agreement with Helsinn Healthcare, SA, a Swiss pharmaceutical corporation, for Pracinostat in AML and other potential indications, including MDS.

http://www.meipharma.com/our-programs/me-401

ME-401 is a potent and selective oral inhibitor of PI3K delta, a molecular target that plays a critical role in the proliferation and survival of certain hematologic cancer cells. Results from a first-in-human, single ascending dose clinical study suggest that ME-401 has the potential for an improved therapeutic window compared to other PI3K delta inhibitors, with a half-life that supports once-daily dosing. A Phase Ib dose-escalation study of ME-401 in patients with recurrent chronic lymphocytic leukemia (CLL) or follicular non-Hodgkin's lymphoma (fNHL) opened for enrollment in September 2016.

http://www.meipharma.com/our-programs/me-344

ME-344 is our isoflavone-derived mitochondrial inhibitor drug candidate. Results from a Phase I clinical study of ME-344 in patients with refractory solid tumors showed evidence of clinical activity, including a confirmed partial response in a heavily pre-treated patient with small cell lung cancer who remained on study for two years. An investigator-sponsored study of ME-344 in combination with the VEGF inhibitor bevacizumab (marketed as Avastin®) in HER2-negative breast cancer opened for enrollment in August 2016.

MEI Pharma is listed on the Nasdaq Capital Market (Nasdaq: MEIP).

Financial Highlights as of September 30, 2016
- $58.9 million in cash
- No debt
- 36.8 million shares outstanding

Company website:
http://www.meipharma.com

Company presentation:
http://www.meipharma.com/sites/default/files/meip_presentation_-_stifel_nov_2016_-_final_2_0.pdf

SureTrader
Interactive Brokers Advertisement
MEIP
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
MEIP News: Additional Proxy Soliciting Materials (definitive) (defa14a) 10/16/2017 09:34:03 AM
MEIP News: Proxy Statement (definitive) (def 14a) 10/16/2017 09:31:44 AM
MEIP News: MEI Pharma to Present at Cantor Fitzgerald Global Healthcare Conference 09/19/2017 09:00:00 AM
MEIP News: Current Report Filing (8-k) 09/06/2017 04:17:02 PM
MEIP News: MEI Pharma Announces Exclusive License Agreement with Presage Biosciences for Voruciclib, An Oral, Selective CDK Inhibitor 09/05/2017 04:05:00 PM
PostSubject
#1255   CPXX was bought for $1.5 billion, as I bladerunner1717 10/14/17 06:16:09 PM
#1254   CPXX was bought for $30 so this could mypekeispooped 10/13/17 11:57:47 PM
#1253   I totally agree. Wish I'd waited till now MC5 10/05/17 04:22:59 PM
#1252   Like your thinking... mandymagoo 10/05/17 01:22:22 PM
#1251   I fully agree! Have owned shares for WAM2 10/04/17 08:08:54 PM
#1250   This is a $20-30 stock, if Pracinostat succeeds bladerunner1717 10/04/17 06:04:25 PM
#1249   So, I've been with MEI for years when MC5 10/04/17 10:42:59 AM
#1248   MEIP presentation today at Biocentury. (Much better than bladerunner1717 09/08/17 11:23:42 AM
#1247   Thanks Blade...good stuff! UFO 09/07/17 06:47:59 PM
#1246   MEIP presentation today at Wells Fargo--notes bladerunner1717 09/07/17 06:07:35 PM
#1245   MEI Pharma Announces Exclusive License Agreement with Presage Shakedown 09/05/17 04:38:11 PM
#1244   MEI Pharma Reports Fiscal Year 2017 Results bladerunner1717 09/05/17 11:18:15 AM
#1243   Great numbers today! Gap up on the UFO 09/05/17 11:05:40 AM
#1242   Good Stuff... wiredawg 08/02/17 03:25:11 PM
#1241   Nice. That's why you do DD. EM 08/02/17 09:36:30 AM
#1240   MEIP announces that the first patient has been bladerunner1717 08/02/17 09:20:34 AM
#1239   Today announced phase3 Borgie 08/02/17 09:18:25 AM
#1238   If they ever get to start P3 rufustherat 08/01/17 02:38:32 PM
#1237   I read earlier, very positive. SA laid UFO 07/11/17 01:45:10 PM
#1236   The bull case for MEIP (from "Seeking Alpha" bladerunner1717 07/11/17 01:23:50 PM
#1235   heading to 6.50 PT "outperform " crudeoil24 07/07/17 11:19:18 AM
#1234   I'm a "momentum can morph into a LT UFO 07/07/17 08:07:52 AM
#1233   What prompted you to get in? Are bladerunner1717 07/06/17 10:37:44 PM
#1232   Got in yesterday, long at $2.53. LOVED UFO 07/06/17 10:18:23 PM
#1231   MEIP keeps setting new 52-week highs on higher bladerunner1717 07/06/17 06:42:28 PM
#1230   Agree! They still have to PR initiation of EM 06/29/17 12:49:36 PM
#1229   MEIP keeps setting new 52-week highs on higher bladerunner1717 06/28/17 04:26:28 PM
#1228   MEIP is playing with my emotions. LOL wiredawg 06/28/17 11:31:37 AM
#1227   Under $2 already...this is crap... wiredawg 06/06/17 04:49:59 PM
#1226   Good news for ME-401!! EM 05/31/17 09:26:54 AM
#1225   Finally broke $2...would like to see this trading wiredawg 05/26/17 02:07:22 PM
#1224   Good volume so far .... EM 05/25/17 02:03:21 PM
#1223   Oppenheimer initiates coverage of MEIP with "outperform." Stock bladerunner1717 05/25/17 11:31:42 AM
#1222   MEI Pharma Reports Third Quarter Fiscal Year 2017 Results bladerunner1717 05/04/17 12:12:11 PM
#1221   Per Helsinn Agreement, tomorrow MEIP will cash in $5mm. EM 02/28/17 05:15:19 PM
#1220   Thanks for that link & GLTALs ringao 02/14/17 08:22:21 AM
#1219   Tutes are increasing their position in MEI Pharma https://fintel.io/so/us/meip EM 02/13/17 08:12:15 AM
#1218   I keep an eye open for new filings rivervalley 02/11/17 03:03:17 PM
#1217   Agreed...I think the market is still holding last wiredawg 02/11/17 12:09:16 PM
#1216   Needs to at least make a move to rivervalley 02/09/17 03:39:25 PM
#1215   Impressive earnings. http://seekingalpha.com/pr/16736414-mei-pharma-reports-seco EM 02/08/17 09:07:36 AM
#1214   Yep, I meant "Initiation of Phase III study EM 01/18/17 03:25:18 AM
#1213   I thought Pracinostat Phase III was a 2018 event. bladerunner1717 01/17/17 08:12:49 PM
#1212   Very nice. Held well. MEIP time is starting. EM 01/17/17 05:59:27 PM
#1211   Yes, both are multimillion market per "global data". Initiation EM 01/07/17 03:36:26 PM
#1210   One of the key elements of the Helsinn bladerunner1717 01/07/17 03:00:00 PM
#1209   Pracinostat looks really better than Azacitdine alone (Median EM 01/07/17 09:25:52 AM
#1208   The bearish case against MEIP is that the bladerunner1717 01/07/17 02:12:23 AM
#1207   Yep... wiredawg 01/06/17 03:33:19 PM
#1206   Thanks. Are you still in? EM 01/06/17 03:27:34 PM
PostSubject